← Search & browse all drugs

tislelizumab

L01FF09

Forms & Strengths

Intravenous infusion: 100 mg per 10 mL single-dose vial

Adult Dosing

Esophageal squamous cell carcinoma: 200 mg IV every 3 weeks until disease progression or unacceptable toxicity
Non-small cell lung cancer: 200 mg IV every 3 weeks in combination with chemotherapy
Gastric or gastroesophageal junction adenocarcinoma: 200 mg IV every 3 weeks

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
First-line treatment of unresectable advanced or metastatic ESCC in combination with platinum-based chemotherapy
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy
Gastric or gastroesophageal junction adenocarcinoma

Mechanism of Action

Humanized monoclonal IgG4 antibody that binds to programmed death receptor-1 (PD-1)
Blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response
Engineered to minimize Fc-gamma receptor binding on macrophages to prevent antibody-dependent cellular phagocytosis

Contraindications

Severe hypersensitivity to tislelizumab or any of its excipients

Adverse Reactions

Musculoskeletal pain and fatigue
Decreased appetite, constipation, and nausea
Rash and pruritus
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis
Infusion-related reactions

Drug Interactions

No formal pharmacokinetic drug-interaction studies have been conducted with tislelizumab
Systemic corticosteroids and immunosuppressants should be avoided before starting tislelizumab due to potential interference with pharmacodynamic activity
Corticosteroids and other immunosuppressants can be used after initiating tislelizumab to manage immune-mediated adverse reactions

Curated Content: Needs Vetting Before Put to Clinical Use